Appeals are mounting in Purdue Pharma bankruptcy settlement
Objections to a historic settlement with Purdue Pharma are mounting in the form of appeals
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Objections to a historic settlement with Purdue Pharma are mounting in the form of appeals, with Rhode Island s attorney general saying Wednesday the plan doesn't hold the OxyContin maker or its owners accountable for its role in sparking the opioid crisis.
Rhode Island appealed Tuesday in U.S. Bankruptcy Court in New York Separate appeals have already been filed by the U.S. Bankruptcy Trustee, California Connecticut the District of Columbia, Maryland and Washington state, plus some Canadian local governments and other Canadian entities.
Any successful appeal could undo the deal, not just that state’s piece of it.
Rhode Island Attorney General Peter Neronha, a Democrat, said he doesn't accept that the resolution between Purdue Pharma and thousands of state and local governments is sufficient. The Sackler family has not been transparent about its wealth, he said, so it's difficult to calculate how much punishment any resolution will inflict.
Estimates have put the collective wealth of family members who own the company at over $10 billion.
Neronha also said he dislikes that the settlement protects the Sacklers from lawsuits over opioids.
The state would be entitled to an estimated $21.6 million over nine years, or about $2.4 million annually, he said.
“It's just not a lot,” Neronha said. “It may sound like a lot, I guess, but it's not a lot, given the scope of the problem, both past, present and future.”
A federal bankruptcy judge approved a plan this month to turn Purdue, based in Stamford, Connecticut, into a new company no longer owned by members of the Sackler family, with its profits going to fight the opioid epidemic.
The deal resolves some 3,000 lawsuits filed by state and local governments, Native American tribes, unions, hospitals and others who claimed the company’s marketing of prescription opioids helped spark and continue an overdose epidemic.
Company profits and $4.5 billion in cash and charitable assets from members of the Sackler family will be used to pay some individual victims and help fund opioid treatment and prevention programs.
Members of the Sackler family have said that while they dispute the allegations made about their family, they “embraced this path in order to help combat a serious and complex public health crisis.”
Purdue has said the settlement averts “years of value-destructive litigation” and ensures that billions of dollars will be used to help people and communities hurt by the opioid crisis. Phone messages left with their lawyers Wednesday were not immediately returned.
Rhode Island's case against opioid makers is scheduled for trial in state court in January. But the state's claim and all others against Purdue were put on pause when the company filed for bankruptcy two years ago. The state's only hope of being able to move ahead with a claim against the company would be winning an appeal.